Pancreatic Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Pancreatic Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month13 studies across 11 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| RADX | Radiopharm Theranostics, Ltd | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-17 |
| VSTM | Verastem, Inc. | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerNCT05669482Part A: To determine RP2D for avutometinib (VS-6766) and defactinib in combination gemcitabine and nab-paclitaxel | Phase 1/2 | Active, not recruiting | 2026-08-31 | in 11 d | 2025-09-02 |
October 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsNCT05663515observationalIncidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population | — | Recruiting | 2026-10-01 | in 42 d | 2026-08-04 |
| PFE | Pfizer | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662Part 1 & 2: Incidence of Adverse Events (AEs) | Phase 1 | Active, not recruiting | 2026-10-09 | in 50 d | 2026-07-22 |
| TEM | Tempus AI | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | 2026-10-19 | in 60 d | 2025-05-06 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. | Phase 2 | Recruiting | 2026-11-17 | in 89 d | 2026-07-29 |
| MGNX | MacroGenics | A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028 | Phase 1 | Recruiting | Nov 2026 | ≤ 102 d | 2026-04-27 |
December 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-07 |
| BCAX | Bicara Therapeutics | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsNCT04429542Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2025-08-15 |
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
| RVMD | Revolution Medicines, Inc. | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541Adverse events | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2026-06-03 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410Rate of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-06-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Pancreatic Cancer
most recently updated first273 studies match. Showing the first 100 of 273 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| BOLD | Boundless Bio, Inc. | $65M | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825 | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2023-03-24 | 2026-03-17actual | — | 2026-08-19 |
| CORT | Corcept Therapeutics | $12.8B | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1) | Phase 2 | Recruiting | Drug: Relacorilant, Nab-paclitaxel, Gemcitabine | Adenocarcinoma, Carcinoma, Pancreatic Ductal | 80 | 2026-01-27 | Sep 2027 | ≤ 406 d | 2026-08-18 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07491445Progression free survival (PFS) | Phase 3 | Recruiting | Drug: daraxonrasib, gemcitabine, nab-paclitaxel | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma | 900 | 2026-03-09 | Jun 2028 | ≤ 680 d | 2026-08-18 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersNCT07769502Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Phase 2 | Not yet recruiting | Drug: Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel | Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma | 168 | 2026-09-22 | Nov 2028 | ≤ 833 d | 2026-08-18 |
| INCY | Incyte Corporation | $24.7B | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940Frequency and types of adverse events and serious adverse events | Phase 2 | Active, not recruiting | Drug: Ruxolitinib, Capecitabine, Regorafenib | Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer | 10 | 2016-11-30 | 2027-09-30 | in 406 d | 2026-08-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaNCT07573215expanded access | — | Available | Drug: daraxonrasib | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma | — | — | — | — | 2026-08-17 |
| VSTM | Verastem, Inc. | $673M | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerNCT07644559Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 | Phase 2 | Recruiting | Drug: VS-7375, cetuximab | Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | 180 | 2026-06-16 | Jun 2027 | ≤ 314 d | 2026-08-17 |
| ABBV | AbbVie | $457.5B | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal AdenocarcinomaNCT07490301Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Phase 2/3 | Recruiting | Drug: Telisotuzumab adizutecan, Fluorouracil, Folinic acid/ Leucovorina, Oxaliplatin, Irinotecan | Metastatic Pancreatic Ductal Adenocarcinoma, PDAC | 900 | 2026-04-30 | Jun 2031 | ≤ 1,775 d | 2026-08-14 |
| IMRX | Immuneering Corporation | $221M | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07562152Overall Survival | Phase 3 | Recruiting | Drug: Atebimetinib, GnP, mGnP | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma | 510 | 2026-06-05 | Jun 2028 | ≤ 680 d | 2026-08-14 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsNCT05985655Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: GTAEXS617, SoC | Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC) | 230 | 2023-07-06 | Jan 2028 | ≤ 529 d | 2026-08-13 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsNCT07066657Dose Limiting Toxicity (DLT) - Phase Ia | Phase 1 | Recruiting | Drug: MRG007, MRG007 and Bevacizumab | Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer | 572 | 2025-07-25 | Mar 2028 | ≤ 589 d | 2026-08-13 |
| BTAI | BioXcel Therapeutics Inc | $25M | A Pilot Study of BXCL701 in Patients With Pancreatic CancerNCT04123574To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action. | Early Phase 1 | Withdrawnsponsor's stated reason: No longer relevant to field | Drug: Talabostat Mesylate | Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreatic Cancer | 0 | 2019-10-15 | 2021-12-06 | — | 2026-08-11 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| AZN | AstraZeneca | — | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours | Phase 1 | Recruiting | Biological: NT-175 | Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS) | 45 | 2023-07-12 | 2029-07-31 | in 1,076 d | 2026-08-06 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | 2025-11-07 | Dec 2027 | ≤ 498 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3) | Phase 1 | Recruiting | Drug: IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | 260 | 2026-03-04 | 2028-04-30 | in 619 d | 2026-08-05 |
| XBIT | XBiotech, Inc. | $69M | XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic CancerNCT04825288results2026-08-04To Establish the Maximum Tolerated Dose (MTD) of XB2001 as Measured by Dose-Limiting Toxicity (DLT), in Combination With ONIVYDE + LV + 5-FU Chemotherapy Regimen in Patients With Advanced Pancreatic Cancer. | Phase 1/2 | Completed | Biological: Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo | Pancreatic Cancer | 76 | 2021-05-27 | 2023-10-26actual | — | 2026-08-04 |
| AZN | AstraZeneca | — | A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsNCT05663515observationalIncidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population | — | Recruiting | Drug: Exenatide, Non-GLP-1 RA based glucose lowering drugs | Pancreatic Cancer | 24,000 | 2024-09-30 | 2026-10-01 | in 42 d | 2026-08-04 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481Objective Response Rate (ORR) | Phase 1 | Active, not recruiting | Drug: ABBV-400, Itraconazole (ITZ), Bevacizumab | Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer | 302 | 2023-11-09 | Sep 2027 | ≤ 406 d | 2026-08-04 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsNCT06128551Number of patients with adverse events (AEs) in Phase 1b | Phase 1/2 | Recruiting | Drug: Elironrasib, Daraxonrasib | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | 534 | 2023-11-14 | Dec 2028 | ≤ 864 d | 2026-08-03 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )NCT07621718Progression free survival (PFS) | Phase 3 | Recruiting | Drug: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma | 670 | 2026-05-22 | 2028-12-30 | in 863 d | 2026-08-03 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT06608927Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine | Metastatic Pancreatic Ductal Adenocarcinoma | 610 | 2024-12-13 | 2030-11-30 | in 1,563 d | 2026-07-31 |
| AZN | AstraZeneca | — | Study for AZD4360 in Participants With Advanced Solid TumoursNCT06921928Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360 | Phase 1/2 | Active, not recruiting | Drug: AZD4360 | Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma | 31 | 2025-04-29 | 2027-03-31 | in 223 d | 2026-07-31 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)NCT07252232Disease-Free Survival (DFS) per Investigator | Phase 3 | Recruiting | Drug: daraxonrasib | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma | 500 | 2025-12-15 | 2029-05-10 | in 994 d | 2026-07-31 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursNCT06305247Phase 1: Percentage of participants with dose limiting toxicity (DLT) | Phase 1/2 | Active, not recruiting | Drug: IPN01194, IPN01194 | Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor | 36 | 2024-04-03 | 2028-03-20 | in 578 d | 2026-07-30 |
| AZN | AstraZeneca | — | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. | Phase 2 | Recruiting | Drug: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine | Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma | 226 | 2023-12-13 | 2026-11-17 | in 89 d | 2026-07-29 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsNCT06445062Adverse events | Phase 1/2 | Recruiting | Drug: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 1,130 | 2024-05-24 | 2027-05-15 | in 268 d | 2026-07-29 |
| AZN | AstraZeneca | — | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumors | Phase 1 | Recruiting | Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D | Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D | 108 | 2024-03-22 | 2027-08-30 | in 375 d | 2026-07-28 |
| BNTX | BioNTech SE | — | A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic CancerNCT07255404Confirmed overall response rate | Phase 2 | Recruiting | Drug: Pumitamig, Nab-paclitaxel, Gemcitabine, mFOLFIRINOX | Pancreatic Ductal Adenocarcinoma (PDAC) | 105 | 2025-12-04 | Dec 2027 | ≤ 498 d | 2026-07-28 |
| AZN | AstraZeneca | — | 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)NCT04553926observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions(ADRs), serious ADRs (SADRs), unexpected AEs/ADRs) | — | Completed | — | Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer | 661 | 2021-02-01 | 2025-07-11actual | — | 2026-07-23 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2022-10-25 | 2028-01-05 | in 503 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma | 914 | 2023-11-20 | 2029-09-12 | in 1,119 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662Part 1 & 2: Incidence of Adverse Events (AEs) | Phase 1 | Active, not recruiting | Drug: PF-07934040 · Combination product: Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab | Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | 64 | 2024-06-27 | 2026-10-09 | in 50 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation | Phase 1 | Recruiting | Drug: PF-08046876 | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer | 310 | 2025-08-20 | 2028-07-08 | in 688 d | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsNCT06607185Number of Participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Active, not recruiting | Drug: LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor | 750 | 2024-10-21 | Jan 2030 | ≤ 1,260 d | 2026-07-20 |
| RADX | Radiopharm Theranostics, Ltd | — | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Drug: RAD301 ([68Ga]-RAD301) | Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer | 9 | 2023-11-09 | Aug 2026 | ≤ 11 d | 2026-07-17 |
| ELTX | Elicio Therapeutics | $82M | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid TumorsNCT05726864Phase 1: Evaluate the safety of ELI-002 7P | Phase 1/2 | Active, not recruiting | Drug: ELI-002 7P | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S | 158 | 2023-04-14 | 2026-04-20actual | — | 2026-07-10 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| ELTX | Elicio Therapeutics | $82M | Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal AdenocarcinomaNCT07083479expanded access | — | No longer available | Drug: ELI-002 7P | Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G12A, KRAS G12C, KRAS G12R, KRAS G13D, NRAS G12D, NRAS G12V, NRAS G12S, NRAS G12A, NRAS G12C, NRAS G12R, NRAS G13D | — | — | — | — | 2026-07-10 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537Number of patients with adverse events (AEs) | Phase 1 | Recruiting | Drug: RMC-5127, daraxonrasib, cetuximab | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors | 574 | 2026-01-08 | Apr 2028 | ≤ 619 d | 2026-07-10 |
| LLY | Eli Lilly and Company | $1.15T | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449results2026-07-09Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin | Phase 1 | Completed | Drug: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin | Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer | 353 | 2013-11-15 | 2019-02-19actual | — | 2026-07-09 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatigueNCT06989437Percent change from baseline in body weight for ponsegromab compared to placebo | Phase 2/3 | Recruiting | Drug: ponsegromab, placebo | Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma | 982 | 2025-10-03 | 2028-01-17 | in 515 d | 2026-07-09 |
| AZN | AstraZeneca | — | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | Drug: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068 | Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma | 13 | 2024-07-31 | 2026-12-31 | in 133 d | 2026-07-07 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-MesoC2 in Advanced Solid TumorsNCT06466187Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Drug: PF-08052666 | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial | 19 | 2024-08-02 | 2026-05-27actual | — | 2026-07-07 |
| CATX | Perspective Therapeutics | $366M | Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756Determination of safety and tolerability of [203Pb]Pb-PSV359 | Phase 1/2 | Recruiting | Drug: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma | 112 | 2025-04-28 | 2028-01-31 | in 529 d | 2026-07-06 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesNCT04104672Number of participants with Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Drug: AB680, Zimberelimab, Nab-paclitaxel, Gemcitabine | Advanced Pancreatic Cancer | 196 | 2019-11-06 | May 2027 | ≤ 284 d | 2026-07-02 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsNCT05571839Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Drug: PF-08046049 | Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma | 41 | 2023-01-03 | 2026-06-01actual | — | 2026-07-01 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403Number of Participants with Adverse Events (AE) | Phase 1 | Recruiting | Drug: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan | Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer | 694 | 2021-11-01 | Jul 2027 | ≤ 345 d | 2026-06-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4170156 in Participants With Selected Advanced Solid TumorsNCT06400472Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156 | Phase 1 | Recruiting | Drug: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumab | Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms | 495 | 2024-05-20 | Feb 2027 | ≤ 192 d | 2026-06-18 |
| LLY | Eli Lilly and Company | $1.15T | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Drug: LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer | 630 | 2024-09-12 | Mar 2029 | ≤ 954 d | 2026-06-18 |
| GEHC | GE Healthcare | $33.0B | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)NCT07219238Per-region sensitivity and Per-region specificity of GEH300079 (68Ga) PET/CT imaging to detect PC. | Phase 2/3 | Recruiting | Drug: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma | 175 | Oct 2026 | Jun 2029 | ≤ 1,045 d | 2026-06-17 |
| AGEN | Agenus Inc. | $339M | A Study of Botensilimab in Participants With Metastatic Pancreatic CancerNCT05630183Progression-free Survival as Assessed by Investigator | Phase 2 | Completed | Drug: Botensilimab, Gemcitabine, Nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma | 81 | 2023-03-27 | 2026-01-05actual | — | 2026-06-11 |
| KURA | Kura Oncology, Inc. | $1.1B | KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410Rate of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: Darlifarnib, Cabozantinib, Adagrasib | Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC) | 300 | 2023-10-18 | Jan 2027 | ≤ 164 d | 2026-06-08 |
| PFE | Pfizer | $155.3B | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15NCT05546476results2025-04-29Part A: Change From Baseline in Body Weight at Week 12 | Phase 2 | Completed | Drug: ponsegromab, Placebo for ponsegromab | Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia | 187 | 2022-11-21 | 2024-03-13actual | — | 2026-06-03 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541Adverse events | Phase 1 | Recruiting | Drug: RMC-9805, RMC-6236 | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors | 604 | 2023-09-07 | 2026-12-31 | in 133 d | 2026-06-03 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)NCT07076121Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1) | Phase 2/3 | Active, not recruiting | Drug: Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo | Pancreatic Ductal Adenocarcinoma | 470 | 2025-10-23 | 2029-05-03 | in 987 d | 2026-06-03 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320Progression free survival (PFS) in the RAS G12-mutant population | Phase 3 | Active, not recruiting | Drug: RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | 500 | 2024-10-16 | Jun 2026 | — | 2026-06-02 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesNCT05783622Incidence of Dose Limiting Toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: JANX008 | Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer | 130 | 2023-04-19 | 2026-07-31 | — | 2026-06-01 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy | Phase 1/2 | Active, not recruiting | Drug: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms | 540 | 2021-07-19 | Apr 2027 | ≤ 253 d | 2026-05-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesNCT07223047Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab | Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | 252 | 2025-11-25 | 2028-10-13 | in 785 d | 2026-05-28 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174 | Phase 1 | Active, not recruiting | Drug: LY4101174 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 490 | 2024-03-05 | Mar 2027 | ≤ 223 d | 2026-05-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.NCT06704724Part 1 & 2: Incidence of Adverse Events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns. | Drug: PF-07985045 · Combination product: Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892 | Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | 30 | 2024-12-10 | 2026-05-12actual | — | 2026-05-22 |
| ONCY | Oncolytics Biotech | $108M | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabNCT07280377Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5 | Phase 1/2 | Active, not recruiting | Drug: Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil, mFOLFIRINOX Treatment Regimen | Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma | 122 | 2021-10-27 | 2027-07-30 | in 344 d | 2026-05-19 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsNCT07094204Incidence of Dose Limiting Toxicities (DLTs) (Dose Escalation only) | Phase 1 | Recruiting | Drug: ASP5834, panitumumab | Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | 364 | 2025-07-25 | 2028-11-30 | in 833 d | 2026-05-18 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT05379985Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs | Phase 1/2 | Recruiting | Drug: RMC-6236 | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors | 754 | 2022-05-31 | 2027-05-31 | in 284 d | 2026-05-15 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsNCT05462717Adverse events | Phase 1 | Active, not recruiting | Drug: RMC-6291 | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor | 222 | 2022-09-19 | 2027-03-31 | in 223 d | 2026-05-15 |
| AGEN | Agenus Inc. | $339M | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalNCT06751524expanded access | — | Available | Drug: Botensilimab, Balstililmab | Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC), Melanoma, Sarcoma, Ovarian Cancer, Prostate Cancer | — | — | — | — | 2026-05-15 |
| TNGX | Tango Therapeutics, Inc. | $4.3B | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsNCT06922591Phase 1: Maximum Tolerated Dose | Phase 1/2 | Recruiting | Drug: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer | 183 | 2025-05-31 | Jun 2027 | ≤ 314 d | 2026-05-14 |
| MRKR | Marker Therapeutics, Inc. | $19M | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic CancerNCT06549751During Dose Escalation - determine the MTD, recommended expansion dose, or MPD of MT-601 administered during maintenance capacitabine following treatment with FOLFIRINOX (FFX) or NALIRIFOX (NLX). | Phase 1 | Not yet recruiting | Drug: MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells, MT-601 dose 1200 million cells | Pancreas Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer (Unresectable) | 38 | 2026-07-16 | 2028-07-16 | in 696 d | 2026-05-13 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsNCT05983133Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Drug: PF-08046052 | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma | 68 | 2023-11-14 | 2026-04-16actual | — | 2026-05-05 |
| PHIL.MI | Philogen S.p.A. | $1.1B | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid TumorsNCT07566897STEP A and STEP B: DLT | Phase 1 | Not yet recruiting | Drug: L19IL2, Ruxolitinib | Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC) | 96 | 2026-05-01 | Dec 2029 | ≤ 1,229 d | 2026-05-05 |
| LTRN | Lantern Pharma Inc. | $32M | Study of LP-184 in Patients With Advanced Solid TumorsNCT05933265To evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0 | Phase 1/2 | Active, not recruiting | Drug: LP-184, Olaparib, Nivolumab & Ipilimumab | Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation | 64 | 2023-06-09 | 2026-07-28 | — | 2026-05-04 |
| NVCR | NovoCure Ltd. | $2.0B | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaNCT06390059Disease control rate (DCR) | Phase 2 | Completed | Device: Tumor Treating Fields · Drug: Atezolizumab, Gemcitabine, nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma | 84 | 2023-08-28 | 2025-11-18actual | — | 2026-04-30 |
| IBRX | ImmunityBio, Inc. | $8.2B | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic CancerNCT07488884Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Not yet recruiting | Drug: Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101), Nab paclitaxel / gemcitabine | Pancreatic Cancer Resectable, Pancreatic Cancer | 30 | 2026-06-01 | 2027-06-01 | in 285 d | 2026-04-29 |
| MGNX | MacroGenics | $261M | A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028 | Phase 1 | Recruiting | Biological: MGC028 | Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma | 124 | 2025-02-13 | Nov 2026 | ≤ 102 d | 2026-04-27 |
| PFE | Pfizer | $155.3B | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesNCT06974734Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns | Drug: PF-08046037, sasanlimab | Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | 8 | 2025-05-06 | 2026-03-20actual | — | 2026-04-23 |
| VSTM | Verastem, Inc. | $673M | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375 | Phase 1/2 | Recruiting | Drug: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine, Gemcitabine + Nab-paclitaxel | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS | 295 | 2025-06-24 | Dec 2028 | ≤ 864 d | 2026-04-22 |
| AZN | AstraZeneca | — | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsNCT06973161observationalOverall Survival | — | Completed | — | Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors | 140 | 2025-06-10 | 2026-03-17actual | — | 2026-04-08 |
| ACTU | Actuate Therapeutics Inc. | $25M | 9-ING-41 in Patients With Advanced CancersNCT03678883Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | Phase 2 | Active, not recruiting | Drug: 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan | Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma | 350 | 2019-01-04 | Jun 2026 | — | 2026-04-03 |
| ERAS | Erasca, Inc. | $6.3B | A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesNCT05039177Dose Limiting Toxicities (DLT) | Phase 1/2 | Completed | Drug: ERAS-007, Encorafenib, Cetuximab, Palbociclib | Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 101 | 2021-09-20 | 2025-08-15actual | — | 2026-03-25 |
| AZN | AstraZeneca | — | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D MutationNCT06599502Incidence of participants with Dose-Limiting Toxicity (DLT), Adverse events (AEs) and Serious Adverse Events (SAEs). | Phase 1 | Terminatedsponsor's stated reason: The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01 (D7080C00001) study was based on strategic company portfolio prioritization. | Drug: AZD0022, Cetuximab | Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) | 17 | 2024-10-18 | 2025-10-20actual | — | 2026-03-18 |
| AZN | AstraZeneca | — | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid TumorsNCT06005493The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD5863 | Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma | 280 | 2023-07-11 | 2027-07-16 | in 330 d | 2026-02-24 |
| CUE | Cue Biopharma | $2.4B | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic CancersNCT05360680Dose Limiting Toxicity | Phase 1 | Completed | Drug: CUE-102 | Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer | 42 | 2022-06-14 | 2025-03-12actual | — | 2026-01-22 |
| NVCR | NovoCure Ltd. | $2.0B | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)NCT03377491results2026-01-21Overall Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone | Phase 3 | Completed | Device: NovoTTF-200T · Drug: Gemcitabine, nab paclitaxel | Pancreas Adenocarcinoma | 571 | 2018-05-10 | 2024-10-16actual | — | 2026-01-21 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | 2025-07-21 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
| AZN | AstraZeneca | — | LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)NCT04889404observationalIncidence of adverse events related to the safety specifications | — | Completed | — | Pancreatic Neoplasms | 130 | 2021-05-22 | 2025-02-06actual | — | 2026-01-14 |
| NUVB | Nuvation Bio Inc. | $2.4B | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsNCT06334432Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumors | Phase 1/2 | Active, not recruiting | Drug: NUV-1511 | Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC) | 466 | 2024-03-14 | Mar 2027 | ≤ 223 d | 2026-01-14 |
| INDP | Indaptus Therapeutics, Inc | $125M | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsNCT05651022Number of Subjects with dose-limiting toxicities (DLTs) | Phase 1/2 | Active, not recruiting | Drug: Decoy20, Tislelizumab | Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer | 120 | 2023-02-28 | 2027-06-30 | in 314 d | 2026-01-13 |
| AAPG | Ascentage Pharma Group Inc. | — | APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaNCT04643405Dose Limiting Toxicities (DLT) of combination therapy (Applicable for: phase Ib stage ). | Phase 1/2 | Terminatedsponsor's stated reason: Company Strategy | Drug: APG-1387 for Injection, Gemcitabine, Nab paclitaxel | Advanced Pancreatic Cancer | 21 | 2021-03-17 | 2024-06-25actual | — | 2026-01-08 |
| CRDF | Cardiff Oncology | $69M | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaNCT04752696Overall Response Rate (ORR) | Phase 2 | Completed | Drug: Onvansertib, Nanoliposomal irinotecan, Leucovorin, Fluorouracil | Pancreatic Ductal Adenocarcinoma | 41 | 2021-05-25 | 2024-12-24actual | — | 2025-12-22 |
| IBRX | ImmunityBio, Inc. | $8.2B | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399Progression Free Survival (PFS) | Phase 2 | Active, not recruiting | Biological: N-803, PD-L1 t-haNK · Drug: Aldoxorubicin HCl, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Irinotecan liposome · Procedure: SBRT | Pancreatic Cancer | 328 | 2020-07-21 | 2025-10-13actual | — | 2025-12-15 |
| BMY | Bristol-Myers Squibb | $134.9B | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionNCT05245500Number of Patients who Experience Dose-Limiting Toxicity | Phase 1 | Recruiting | Drug: MRTX1719 | Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor | 336 | 2022-06-09 | 2027-12-10 | in 477 d | 2025-12-05 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsNCT05795595Phase 1 (Dose Escalation): Incidence of adverse events | Phase 1/2 | Completed | Biological: CTX131 | Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma | 19 | 2023-03-13 | 2025-09-18actual | — | 2025-11-26 |
| TCRT | Alaunos Therapeutics | $5M | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsNCT05194735results2025-11-10Number of Participants With Treatment-Emergent Adverse Events | Phase 1/2 | Terminatedsponsor's stated reason: Funding | Biological: Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2) | Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer | 8 | 2022-04-04 | 2023-08-14actual | — | 2025-11-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Pancreatic Cancer is matched — 24 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Neoplasms
- Pancreas Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
- PDAC
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Cancer
- Pancreatic Carcinoma
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer Metastatic
- Carcinoma, Pancreatic Ductal
- Metastatic Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Neoplasm
- Advanced Pancreatic Cancer
- Pancreas Adenocarcinoma
- Pancreatic Adenosquamous Carcinoma
- Stage III Pancreatic Cancer
- Pancreatic Cancer (Unresectable)
- Pancreatic Ductal Carcinoma
- Stage IV Pancreatic Cancer
- Unresectable Pancreatic Cancer
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Pancreatic Cancer” (a text search, wider than this page)